Amgen nabs another PCSK9 exclusive, this time with giant CVS

Amgen's ($AMGN) PCSK9 med Repatha and Sanofi ($SNY) and Regeneron's ($REGN) competitor Praluent may have both nabbed coverage from top PBM Express Scripts ($ESRX). But now, Amgen has inked an exclusive pact with the giant's archrival, CVS ($CVS). It's the second exclusive Amgen has grabbed for the cholesterol fighter this month; the biotech also negotiated a pay-for-performance deal with the health plan Harvard Pilgrim, gaining an exclusive spot on the payer's formulary in return for an upfront discount and future rebates if Repatha doesn't perform as outlined. More from FiercePharma

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

Roche Canada's new innovation challenge to fight COVID-19 has an April 10 deadline and promises up to $100,000 to fund development.

Merck, Eli Lilly and Pfizer have launched or expanded volunteer programs to dedicate medical workers to the COVID-19 effort.